Lipid-lowering and antioxidant properties of probiotic Bifidobacterium animalis MSMC83 in rats on a high-fat diet.


Journal

Beneficial microbes
ISSN: 1876-2891
Titre abrégé: Benef Microbes
Pays: Netherlands
ID NLM: 101507616

Informations de publication

Date de publication:
11 Oct 2024
Historique:
received: 21 04 2024
accepted: 05 09 2024
medline: 17 10 2024
pubmed: 17 10 2024
entrez: 16 10 2024
Statut: aheadofprint

Résumé

Hyperlipidaemia, the abnormally high concentration of lipids such as cholesterol in the body, has a series of deleterious effects on health that are least in part are due to increased inflammation and oxidative stress. Probiotics are living microorganisms that possess the efficacy to improve health. Among the many effects that have been ascribed to probiotics is the potential to lower the body lipid content. Here, we used a rat model of induced hyperlipidaemia to assess the lipid-lowering and antioxidant properties of the probiotic strain Bifidobacterium animalis MSMC83 as well as its impact on intestinal barrier immunity and the intestinal microbiota. Oral probiotic intake led to a reduction of body weight, fasting blood glucose, and lipid levels, and increased expression of cholesterol-7α-hydroxylase and antioxidant enzymes. Additionally, B. animalis MSMC83 decreased the levels of liver enzymes and pro-inflammatory cytokines, leading to reduced hepatic steatosis. Furthermore, it re-established intestinal barrier integrity as shown by restoration of the tight junction protein zonula occludens-1 amount and reduced pathogen-induced inflammation in the intestinal epithelium as shown by readjusted expression of toll-like receptors (TLRs). Moreover B. animalis MSMC83 contributed to the maintenance of a balanced, diverse microbiome. Thus, our results indicate that B. animalis MSMC83 alleviates risk factors associated with hyperlipidaemia, suggesting its use as a probiotic to counter the effects associated with unhealthy diets.

Identifiants

pubmed: 39414243
doi: 10.1163/18762891-bja00043
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-16

Auteurs

C Chantarangkul (C)

Molecular Biology Program, Faculty of Medicine, Srinakharinwirot University, 114 Sukhumvit 23, Wattana, Bangkok 10110, Thailand.

P Phuengmaung (P)

Center of Excellence on Translational Research in Inflammation and Immunology (CETRII), Faculty of Medicine, Chulalongkorn University, Rama IV road, Bangkok, 10330, Thailand.

A Leelahavanichkul (A)

Center of Excellence on Translational Research in Inflammation and Immunology (CETRII), Faculty of Medicine, Chulalongkorn University, Rama IV road, Bangkok, 10330, Thailand.
Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV road, Bangkok, 10330, Thailand.

P Piewngam (P)

Pathogen Molecular Genetics Section, Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, 50 South Drive, Bethesda, Maryland, 20814, USA.
Summit Therapeutics, 2882 Sand Hill Road, Menlo Park, CA 94025, USA.

M Otto (M)

Pathogen Molecular Genetics Section, Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, 50 South Drive, Bethesda, Maryland, 20814, USA.

M Taweechotipatr (M)

Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, 114 Sukhumvit 23, Wattana, Bangkok, 10110, Thailand.
Center of Excellence in Probiotics, Srinakharinwirot University, 114 Sukhumvit 23, Wattana, Bangkok, 10110, Thailand.

Classifications MeSH